Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|May 4, 2026
5 FDA Decisions for Primary Care to Know from April 2026
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.
Advertisement
Advertisement
In April, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning obesity management, infectious disease, rare genetic conditions, and diabetes care. The following list highlights 5 key updates for primary care, including approval of a novel oral GLP-1 receptor agonist for weight management, a new 2-drug regimen for virologically suppressed HIV, a first-in-class gene therapy for inherited hearing loss, and expanded use of automated insulin delivery technology in pregnancy.
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement